Network Meeting – Rome, Italy – February 9th-10th, 2023

Highlights in therapy-related myeloid neoplasms

Day 1

12:00 - 13:50

Registration + light “Get Together” lunch

13:50 – 14:00

Welcome address: M.T. Voso and D. Capone

Clinical picture of t-MN
Chairs: A. Venditti, G. Leone

14:00 – 14:25

Overview and epidemiology of therapy-related myeloid neoplasms (L.S. Granfeldt-Ostgard, Denmark)

14:30 – 14:55

2022 update of AML classification (K. Döhner, Germany)

15:00 – 15:25

Clinical presentation of t-MN (F. Buccisano, Italy)

15:30 – 15:55

Genetic susceptibility to AML (J. Allan, UK)

16:00 - 16:30

Coffee break

Biology of t-MN
Chairs: K. Döhner, C. Niemeyer

16:30 – 16:55

Cytogenetic and molecular profile of t-MN (S. Galimberti, Italy)

17:00 – 17:25

Clonal Evolution in Therapy-related myeloid neoplasms (E. Fabiani, Italy)

17:30 – 17:55

Microenvironment involvement in t-MN (G. Falconi, Italy)

Day 2

New perspectives for t-MN research and care
Chairs:  G. Ciliberto, L. Pagano

09:00 – 09:25

t-MN: The oncologist's point of view (D. Lorusso, Italy)

09:30 – 09:55

Biology of t-APL (T. Ottone, Italy)

10:00 – 10:25

Clinical presentation and outcome of t-APL (R. Dillon, UK)

10:30 – 10:55

t-MN following childhood malignancies (F. Locatelli, Italy)

11:00 - 11:30

Coffee break

11:30 - 12:30

Selected abstract presentations by early career scientists
Chairs: M.T. Voso, K. Döhner

12:30 – 13:30

Round table “The patient social point of view”
Chairs: G. Martini and G. Ciliberto
B. Ryll, F. Bombaci, A. Sidoli

13:30 - 14:00

Light lunch

Leukaemogeneic drugs and treatment of t-MN
Chairs:  J. Mayer,  M.K.Yuksel

14:00 – 14:25

Leukaemogenic effects of Topoisomerase inhibitors, alkylating agents and new drugs (R. Danesi, Italy)

14:25 – 14:50

Available therapeutic options and new treatments for t-MN (L. Fianchi, Italy)

14:55 – 15:15

Closing Remarks